1 results match your criteria: "Klinikum Stuttgart and Stuttgart Cancer Center - Tumor Center Eva Mayr-Stihl[Affiliation]"
The Treatment of Metastatic Renal Cell Carcinoma.
Dtsch Arztebl Int
August 2024
Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH); Claudia von Schilling, Comprehensive Cancer Center Hannover; Interdisciplinary Work Group Renal Cell CarcinomaI of AUO and AIO at DKG (IAGN-DKG); West German Cancer Center, Clinic for Internal Medicine and Clinic for Urology, University Hospital Essen, Essen, Germany (AöR); Department Medical Hospital VI, University Medical Center Heidelberg, National Center for Tumor Diseases, Heidelberg; Department of Urology, Klinikum Stuttgart and Stuttgart Cancer Center - Tumor Center Eva Mayr-Stihl, Stuttgart; Urologikum Lübeck.
Background: Approximately 15 000 people receive a diagnosis of renal cell carcinoma (RCC) in Germany each year; in 20-30% of cases, metastatic RCC (mRCC) is already present at the time of diagnosis. This disease in the metastatic stage is still mainly treated palliatively, yet the multimodal therapeutic landscape has changed markedly over the past 15 years, with the approval of many new treatments for patients with mRCC.
Methods: This review is based on prospective studies retrieved by a selective search in PubMed and the ASCO and ESMO databases and on the German and European oncological and urological guidelines for RCC.